What is the 13F Pro Quality Score for LUCD?

13F Pro ranks Lucid Diagnostics Inc. (LUCD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LUCD's current score at https://13fpro.ai/research/LUCD (free sign-up required for the full ranking).

Where does 13F Pro source LUCD data?

All Lucid Diagnostics Inc. fundamentals and ownership data come directly from SEC EDGAR. Lucid Diagnostics Inc. files with the SEC under CIK 1799011. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LUCD in?

Lucid Diagnostics Inc. (LUCD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LUCD research updated on 13F Pro?

LUCD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lucid Diagnostics Inc.(LUCD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1799011 LUCD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $4.7M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

LUCD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lucid Diagnostics Inc. (LUCD), a Healthcare sector company. LUCD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), Lucid Diagnostics Inc. reports quarterly revenue of $1.3M, net income of $-13.9M, free cash flow of $-12.3M. Top institutional holders of LUCD by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, MASTERS CAPITAL MANAGEMENT, based on the most recent SEC filings. LUCD trades on the Nasdaq exchange and files with the SEC under CIK 1799011. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LUCD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lucid Diagnostics Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$1.3M

Net Income

Q1 2026

$-13.9M

Free Cash Flow

Q1 2026

$-12.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.3% YoY

$4.7MFY 2025

FY20 —FY21 $500.0KFY24 $4.3MFY25 $4.7M

Net Income

-27.4% YoY

$-58.0MFY 2025

FY20 $-8.3MFY21 $-28.1MFY24 $-45.5MFY25 $-58.0M

Operating Income

-7.8% YoY

$-49.6MFY 2025

FY20 $-8.3MFY21 $-27.4MFY24 $-46.1MFY25 $-49.6M

EPS (Diluted)

—FY 2025

FY20 —FY21 —FY24 $-1.05FY25 —

Total Assets

+31.7% YoY

$40.4MFY 2025

FY20 $2.2MFY21 $59.0MFY24 $30.7MFY25 $40.4M

Total Debt

—FY 2025

FY20 $13.3MFY21 —FY24 —FY25 —

Op. Cash Flow

-5.3% YoY

$-46.5MFY 2025

FY20 $-5.6MFY21 $-17.7MFY24 $-44.1MFY25 $-46.5M

Metric	FY 2025	FY 2024	FY 2021	FY 2020
Revenue	$4.7M +8.3%	$4.3M +769.2%	$500.0K	—
Net Income	$-58.0M -27.4%	$-45.5M -62.2%	$-28.1M -239.1%	$-8.3M
Operating Income	$-49.6M -7.8%	$-46.1M -68.0%	$-27.4M -231.1%	$-8.3M
EPS (Diluted)	—	$-1.05	—	—
Total Assets	$40.4M +31.7%	$30.7M -47.9%	$59.0M +2588.0%	$2.2M
Total Debt	—	—	—	$13.3M
Operating Cash Flow	$-46.5M -5.3%	$-44.1M -149.8%	$-17.7M -213.9%	$-5.6M

AI Insight: LUCD Financial Trends

Lucid Diagnostics remains pre-revenue with flat sales and persistent operating losses; equity volatility signals cash burn strain.

• Revenue stalled at $1–2M across 9 quarters (Q2 2024–Q1 2026); no growth trajectory visible.

• Operating losses widened to $14M in Q4 2025, from $11M in Q2 2024; no margin improvement.

• Operating cash flow consistently negative, ranging $10–13M per quarter; no self-sufficiency.

⚠ Equity swung $-5M (Q1 2025) to $26M (Q3 2025) to $4M (Q1 2026)—extreme volatility suggests dilution and/or revaluation pressure.

⚠ Net loss spiked to $27M in Q1 2025, then moderating but remaining $10–16M quarterly; underlying cash burn unresolved.

AI Insight: LUCD Ratio Trends

Insufficient data to characterize trends — only two quarters show any profitability metrics, both deeply negative.

• Q2 2025 ROA was -45.9%; Q3 2025 deteriorated further to -78.2%, signaling severe profitability pressure.

⚠ ROE collapsed to -161.0% in Q3 2025. Persistent negative returns indicate fundamental operational or capital structure stress.

⚠ No margin, cash flow, or leverage data available across any period. Cannot assess operational efficiency or balance-sheet health.

Get alerted when LUCD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lucid Diagnostics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LUCD

BlackRock, Inc.
$5.3M4,638,243 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.8M4,154,770 sh
MASTERS CAPITAL MANAGEMENT LLC
$4.6M4,000,000 sh
abrdn plc
$4.2M3,644,277 sh
Two Seas Capital LP
$3.5M3,000,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.6M2,245,350 sh
Russell Investments Group, Ltd.
$1.8M1,583,608 sh
STATE STREET CORP
$1.8M1,554,581 sh
WELLS FARGO & COMPANY/MN
$1.5M1,274,390 sh
PERKINS CAPITAL MANAGEMENT INC
$1.3M1,126,000 sh

Fund	Value	Shares
BlackRock, Inc.	$5.3M	4,638,243
VANGUARD CAPITAL MANAGEMENT LLC	$4.8M	4,154,770
MASTERS CAPITAL MANAGEMENT LLC	$4.6M	4,000,000
abrdn plc	$4.2M	3,644,277
Two Seas Capital LP	$3.5M	3,000,000
GEODE CAPITAL MANAGEMENT, LLC	$2.6M	2,245,350
Russell Investments Group, Ltd.	$1.8M	1,583,608
STATE STREET CORP	$1.8M	1,554,581
WELLS FARGO & COMPANY/MN	$1.5M	1,274,390
PERKINS CAPITAL MANAGEMENT INC	$1.3M	1,126,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LUCD on your watchlist

Track score changes the day Lucid Diagnostics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LUCD a good stock to buy?

13F Pro's AI-powered analysis of Lucid Diagnostics Inc. (LUCD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LUCD are available on the LUCD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LUCD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LUCD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lucid Diagnostics Inc.'s investment landscape.